Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Retained Earnings (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Retained Earnings for 16 consecutive years, with $629000.0 as the latest value for Q4 2025.

  • Quarterly Retained Earnings rose 100.36% to $629000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $629000.0 through Dec 2025, up 100.36% year-over-year, with the annual reading at $629000.0 for FY2025, 100.36% up from the prior year.
  • Retained Earnings hit $629000.0 in Q4 2025 for Vanda Pharmaceuticals, up from -$253.6 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $702000.0 in Q3 2024 to a low of -$253.6 million in Q3 2025.
  • Historically, Retained Earnings has averaged -$65.6 million across 5 years, with a median of -$624000.0 in 2023.
  • Biggest five-year swings in Retained Earnings: plummeted 580873.33% in 2024 and later soared 220.0% in 2025.
  • Year by year, Retained Earnings stood at -$175000.0 in 2021, then crashed by 581.71% to -$1.2 million in 2022, then soared by 97.49% to -$30000.0 in 2023, then tumbled by 580873.33% to -$174.3 million in 2024, then skyrocketed by 100.36% to $629000.0 in 2025.
  • Business Quant data shows Retained Earnings for VNDA at $629000.0 in Q4 2025, -$253.6 million in Q3 2025, and $396000.0 in Q2 2025.